A separate analysis of the real-world trial found that those who switched from daily antiretroviral treatment to Cabenuva had fewer concerns about treatment.

The World Health Organization has suggested global release of lenacapavir, a twice-yearly injectable medication, as a powerful HIV infection-fighting medication. The historic suggestion was made ...

IAS – the International AIDS Society – welcomes the bipartisan move in the US Senate to protect the President’s Emergency Plan for AIDS Relief (PEPFAR) from proposed USD 400 million cuts in President ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

The World Health Organization (WHO) released today new guidelines recommending the use of injectable lenacapavir (LEN) twice ...

The World Health Organisation (WHO) has for the first time recommended the use of injectable lenacapavir (LEN) as a ...